Status:

RECRUITING

Quantification of Brain and Kidney Perfusion Before, During, and After Hypothermia Treatment in Neonates With Perinatal Asphyxia Using Contrast-enhanced Ultrasound

Lead Sponsor:

University of Erlangen-Nürnberg Medical School

Conditions:

Perinatal Asphyxia

Hypothermia Treatment

Eligibility:

All Genders

Brief Summary

In this clinical study vascular dynamics in the neonatal brain and kidney will be monitored by CUES and ULM before, during and after hypothermia treatment in neonates with asphyxia.

Detailed Description

Perinatal asphyxia (PA) is the reduced supply of oxygen to vital organs during or immediately after birth. PA is one of the most common causes of neonatal mortality in full-term infants worldwide and ...

Eligibility Criteria

Inclusion

  • Fulfillment of the inclusion criteria for hypothermia treatment according to the AWMF guideline
  • Severe acidosis (pH ≤7.0 or a base deficit ≥16 mmol/l) in umbilical cord blood or a blood sample from the first hour of life, and
  • clinical signs of moderate or severe encephalopathy (severity grade 2 or 3 according to Sarnat \& Sarnat), and
  • postnatal age ≤6h, and
  • gestational age ≥36 weeks' gestation
  • Consent of the parents/legal guardians
  • Time 1 (before the start of hypothermia treatment)
  • Informing the parents/legal guardians present on site despite an emotionally stressful situation with high individual benefit for the patient
  • If only one parent is present and able to provide information, their consent is sufficient - the second parent is informed repeatedly when they regain the ability to provide information
  • Information adapted to the emergency situation, addressing the personal situation and comprehensible presentation of the plan
  • Time 2 (during hypothermia treatment)
  • -\>Offer of a further informative discussion/repeated explanation with the parents/legal representatives before the second measurement in order to answer any questions that may have arisen
  • Suitable acoustic window
  • Availability of the qualified examiner

Exclusion

  • Lack of consent of at least one parent
  • Pre-existing brain malformations
  • Absence of the competent examiner

Key Trial Info

Start Date :

June 24 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06611254

Start Date

June 24 2024

End Date

December 1 2027

Last Update

September 24 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

FAU Erlangen-Nuernberg

Erlangen, Bavaria, Germany, 91054